Kijimea® K53
Product Description
Synformulas GmbH
-
Country/Region:Germany
-
On CPHI since:2021
-
Certificates:3
-
Employees:100 - 249
Company types
Categories
Synformulas GmbH
-
Country/Region:Germany
-
On CPHI since:2021
-
Certificates:3
-
Employees:100 - 249
Company types
More Products from Synformulas GmbH (2)
-
Product Kijimea® IBS PRO
Kijimea® IBS PRO is the development of the medical device Kijimea® IBS. With the patch effect of the heat-inactivated bifidobacterial strain B. bifidum HI-MIMBb75, Kijimea® IBS PRO combats all intestinal complaints of IBS such as diarrhoea, abdominal pain, flatulence, or constipation even more effectiv... -
Product Kijimea® Regularis
Kijimea® Regularis contains the unique Synformularis2 fibre complex. Thanks to its special structure, it is activated by water within a few seconds, but only swells in the intestine.
This gently stretches the intestinal muscles. It receives an impulse to move normally again. The food in...
Synformulas GmbH resources (1)
-
Brochure Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial
Summary
Background Bifidobacterium bifidum MIMBb75 is one of a few probiotic strains that have been shown to be effective inthe treatment of irritable bowel syndrome (IBS) and its symptoms. Non-viable strains might have advantages over viablebacteria for product stability and standardisation, as well as for tolerability because safety concerns have been raised forspecific patient groups who are susceptible to infection. We aimed to assess the efficacy of non-viable, heat-inactivated(HI) B bifidum MIMBb75 (SYN-HI-001) in the treatment of IBS and its symptoms.
Link: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30056-X/fulltext
DOI: https://doi.org/10.1016/S2468-1253(20)30056-X